News
6don MSN
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little ...
CEO Christopher Gibson was one of those sellers, with a Thursday reveal that he had sold 40,390 shares of Recursion's common stock. Chief R&D and commercial officer Najit Khan was also a seller; she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback